Agenus provides 2026 strategic priorities

The company said, “2026 Strategic Priorities: Support responsible authorized access through France’s AAC framework and paid named-patient programs in select countries, with BAP Pharma serving as global access partner; Continue regulatory engagement, including planned accelerated approval and conditional marketing authorization pathways, supported by clinical data and real-world experience generated through authorized access pathways where applicable; Advance global BATTMAN trial enrollment in partnership with CCTG and participating academic networks; Maintain disciplined capital allocation and continue strengthening the balance sheet; Continue clinical and translational data generation across BOT+BAL programs.”